Fulacimstat (BAY1142524)

DRUG3 trials

Sponsors

Bayer

Conditions

Clinical Trial, Phase IDiabetic Kidney DiseaseMyocardial Infarction

Phase 1

Renal Impairment Study

CompletedNCT03402438

BayerClinical Trial, Phase I

Start: 2018-02-12End: 2019-03-19Updated: 2020-03-16

Phase 2

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

CompletedNCT02976467

BayerMyocardial Infarction

Start: 2016-12-30End: 2018-09-04Updated: 2019-09-03

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

CompletedNCT03412006

BayerDiabetic Kidney Disease

Start: 2018-02-02End: 2019-10-10Updated: 2022-03-03